CoChat
Sign Up
Cited by 268Dermatological diseases and infestationsParasitic Diseases Research and TreatmentDermatology and Skin Diseases

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Mass drug administration for scabies control in a population with endemic disease.

Open access
Romani, Lucia, Whitfeld, Margot J., Koroivueta, Josefa, Kama, Mike, Wand, Handan, Tikoduadua, Lisi, Tuicakau, Meciusela, Koroi, Aminiasi, Andrews, Ross, Kaldor, John M., Steer, Andrew C.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1500987
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Scabies is an underrecognized cause of illness in many developing countries. It is associated with impetigo, which can lead to serious systemic complications. We conducted a trial of mass drug administration for scabies control in Fiji. METHODS: We randomly assigned three island communities to one of three different interventions for scabies control: standard care involving the administration of permethrin to affected persons and their contacts (standard-care group), mass administration of permethrin (permethrin group), or mass administration of ivermectin (ivermectin group). The primary outcome was the change in the prevalence of scabies and of impetigo from baseline to 12 months. RESULTS: A total of 2051 participants were enrolled; 803 were in the standard-care group, 532 in the permethrin group, and 716 in the ivermectin group. From baseline to 12 months, the prevalence of scabies declined significantly in all groups, with the greatest reduction seen in the ivermectin group. The prevalence declined from 36.6% to 18.8% in the standard-care group (relative reduction in prevalence, 49%; 95% confidence interval [CI], 37 to 60), from 41.7% to 15.8% in the permethrin group (relative reduction, 62%; 95% CI, 49 to 75), and from 32.1% to 1.9% in the ivermectin group (relative reduction, 94%; 95% CI, 83 to 100). The prevalence of impetigo also declined in all groups, with the greatest reduction seen in the ivermectin group. The prevalence declined from 21.4% to 14.6% in the standard-care group (relative reduction, 32%; 95% CI, 14 to 50), from 24.6% to 11.4% in the permethrin group (relative reduction, 54%; 95% CI, 35 to 73), and from 24.6% to 8.0% in the ivermectin group (relative reduction, 67%; 95% CI, 52 to 83). Adverse events were mild and were reported more frequently in the ivermectin group than in the permethrin group (15.6% vs. 6.8%). CONCLUSIONS: Mass drug administration, particularly the administration of ivermectin, was efficacious for the control of scabies and impetigo. (Funded by the Australian National Health and Medical Research Council; Australian New Zealand Clinical Trials Registry number, ACTRN12613000474752.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1500987

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. Lawrence G, 2005, Bull World Health Organ, 83, 34
  2. Thomas M, 2005, N Z Med J, 118, U1492
  3. 1995, World Health Organ Tech Rep Ser, 852, 1
  4. Strong M, 2007, Cochrane Database Syst Rev, CD000320
  5. 2004, Filaria J, 2, S2

Cited by

Sorted by citations

See all 268

Related

See all

Metadata

Authors
Romani, L., Whitfeld, M. J., Koroivueta, J., Kama, M., Wand, H., Tikoduadua, L., Tuicakau, M., Koroi, A., Andrews, R., Kaldor, J. M., & Steer, A. C.
Affiliations
  • Royal Children's Hospital (AU)
  • St Vincent's Hospital Melbourne (AU)
  • UNSW Sydney (AU)
  • Charles Darwin University (AU)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2015-12-10
Volume
373
Issue
24
Pages
2305-2313
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1500987
OpenAlex
W2317702186
Cited by
268
References
39
Citations by year
2026: 12 · 2025: 16 · 2024: 21 · 2023: 26 · 2022: 20 · 2021: 37 · 2020: 30 · 2019: 30 · 2018: 33 · 2017: 23 · 2016: 19 · 2015: 1
FWCI
19.68
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • CDU eSpace Institutional Repository (Charles Darwin University) (submittedVersion)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Dermatological diseases and infestations
  • Health Sciences › Medicine › Infectious Diseases › Parasitic Diseases Research and Treatment
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
Keywords
scabies, mass drug administration, ivermectin, permethrin, impetigo, scabies control, endemic disease, Fiji, adverse events, community-based intervention, contact treatment
MeSH terms
Administration, Cutaneous, Adolescent, Adult, Anti-Bacterial Agents, Child, Child, Preschool, Female, Fiji, Humans, Impetigo, Insecticides, Ivermectin, Male, Scabies, Prevalence, Endemic Diseases, Permethrin, Young Adult, Skin Cream

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review